UEG 2025 4 - 7 October 2025

Weight-independent benefits of semaglutide on histology and non-invasive tests in participants with biopsy-defined metabolic dysfunction-associated steatohepatitis: Post hoc analysis of the ESSENCE trial part 1

Authors :

Philip N. Newsome^1,2; Matthew J. Armstrong³; Igor Bakulin⁴; Adel Belloum⁵; Anja Geerts^6,7; Jacob George⁸; Ewa Janczewska⁹; Niels Krarup⁵; Chun-Jen Liu^10,11; Håvard Midgard¹²; Vlad Ratziu¹³; Mary Rinella¹⁴; Michael Roden^15,16,17; Arun J. Sanyal¹⁸; Jörn M. Schattenberg¹⁹; Mohamed Tawfik⁵; Thea Vestergaard⁵; Elisabetta Bugianesi²⁰; on behalf of the ESSENCE Study Group

Affiliations

View Details Hide Details

Keywords

MASH

Congress oral presentation

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

Weight-independent benefits of semaglutide on histology and non-invasive tests in participants with biopsy-defined metabolic dysfunction-associated steatohepatitis: Post hoc analysis of the ESSENCE trial part 1

Search Science Hub

Are you a healthcare professional?

Weight-independent benefits of semaglutide on histology and non-invasive tests in participants with biopsy-defined metabolic dysfunction-associated steatohepatitis: Post hoc analysis of the ESSENCE trial part 1​

Weight-independent benefits of semaglutide on histology and non-invasive tests in participants with biopsy-defined metabolic dysfunction-associated steatohepatitis: Post hoc analysis of the ESSENCE trial part 1